Product Information
AFREZZA ((REGULAR INSULIN) 8 UNIT CARTRIDGE is a brand product labeled by Mannkind Corporation, priced at $10.3754 per EA under NDC 47918087890. Its NADAC has been published 102 times since Oct 23, 2024.
Strength
8 [arb'U]/1
Manufacturer
Mannkind CorporationNDC
47918087890
Classification
Brand
Dosage Form
POWDER, METERED
Route
RESPIRATORY (INHALATION)
Effective Date
9/23/2026
Active Ingredients
INSULIN HUMANApproval Type
Biologic (BLA)
FDA Application
BLA022472On Market Since
7/1/2017
Pharmacological Classes
Price Statistics
The NADAC for AFREZZA ((REGULAR INSULIN) 8 UNIT CARTRIDGE has been published 102 times since Oct 23, 2024, and over the history we have for it it has risen 7.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $10.3754 per EA |
|---|---|
| All-time high | $10.3754 (Sep 30, 2026) |
| All-time low | $9.6209 (Oct 23, 2024) |
| 52-week high | $10.3754 |
| 52-week low | $10.0511 |
| Median price | $10.1057 |
| Average price | $10.1270 |
| Largest weekly change | +5.0% (Dec 18, 2024) |
| Weeks tracked | 102 |
| Tracking since | Oct 23, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the INSULIN HUMAN market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Mannkind Corporation manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
INSULIN HUMAN market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Insulin class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of AFREZZA ((REGULAR INSULIN) 8 UNIT CARTRIDGE?
The current National Average Drug Acquisition Cost (NADAC) for AFREZZA ((REGULAR INSULIN) 8 UNIT CARTRIDGE, manufactured by Mannkind Corporation, is $10.3754 per EA (NDC 47918087890), effective Sep 30, 2026.
How has the price of AFREZZA ((REGULAR INSULIN) 8 UNIT CARTRIDGE changed over time?
Over the history we have for it, the NADAC for AFREZZA ((REGULAR INSULIN) 8 UNIT CARTRIDGE has risen 7.8%. It has been tracked across 102 weekly CMS publications since Oct 23, 2024.
What are the highest and lowest recorded NADAC prices for AFREZZA ((REGULAR INSULIN) 8 UNIT CARTRIDGE?
Since Oct 23, 2024, the NADAC for AFREZZA ((REGULAR INSULIN) 8 UNIT CARTRIDGE has ranged from a low of $9.6209 (Oct 23, 2024) to a high of $10.3754 (Sep 30, 2026), with a median of $10.1057 per EA.
Are there cheaper alternatives to AFREZZA ((REGULAR INSULIN) 8 UNIT CARTRIDGE?
No other NADAC-published product currently shares the active ingredient and strength of AFREZZA ((REGULAR INSULIN) 8 UNIT CARTRIDGE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures AFREZZA ((REGULAR INSULIN) 8 UNIT CARTRIDGE?
AFREZZA ((REGULAR INSULIN) 8 UNIT CARTRIDGE (NDC 47918087890) is labeled by Mannkind Corporation, and CMS classifies it as a brand product.